Flag of the European Union EU Clinical Trials Register Help

Clinical trials for influenza AND (QIV OR QUADRIVALENT)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: influenza AND (QIV OR QUADRIVALENT). Displaying page 3 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2013-000372-15 Sponsor Protocol Number: 117036 Start Date*: 2013-10-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, open-label, multicentre clinical trial to assess the immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with GSK Biologica...
    Medical condition: Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults ≥ 50 years of age [YOA ] and immunocompromised adults ≥ 18 YOA.)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    17.1 10021881 - Infections and infestations 10019972 Herpes viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001894-26 Sponsor Protocol Number: CP-PRO-QVLP-014 Start Date*: 2018-10-18
    Sponsor Name:Medicago R&D Inc.
    Full Title: A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Ad...
    Medical condition: Seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-001239-38 Sponsor Protocol Number: CP-PRO-QVLP-012 Start Date*: 2017-10-23
    Sponsor Name:Medicago R&D Inc.
    Full Title: A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64...
    Medical condition: Seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001857-29 Sponsor Protocol Number: V130_14 Start Date*: 2019-03-13
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to...
    Medical condition: Prophylaxis of influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-000576-19 Sponsor Protocol Number: VAP00026 Start Date*: 2022-07-29
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared with Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000116-42 Sponsor Protocol Number: BioVacSafe-QIV Start Date*: 2017-03-02
    Sponsor Name:Ghent University Hospital
    Full Title: A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus...
    Medical condition: Healthy Volunteers - a quadrivalent inactivated split virus influenza vaccine
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003701-26 Sponsor Protocol Number: D2560C00013 Start Date*: 2018-10-11
    Sponsor Name:MedImmune LLC
    Full Title: A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002691-39 Sponsor Protocol Number: APHP200039 Start Date*: 2022-04-27
    Sponsor Name:Assistance Publique-Hôpitaux de Paris
    Full Title: INTERVENTIONAL RESEARCH PROTOCOL INVOLVING HUMAN PARTICIPANTS CONCERNING A MEDICINAL PRODUCT FOR HUMAN USE
    Medical condition: Obese adult patients with BMI ≥35 kg/m2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001638-12 Sponsor Protocol Number: mRNA-1010-P302 Start Date*: 2022-09-29
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older.
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) EE (Completed) BG (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000577-11 Sponsor Protocol Number: VAP00027 Start Date*: 2022-07-29
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-002883-15 Sponsor Protocol Number: V130_12 Start Date*: 2017-07-19
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine C...
    Medical condition: Profylaxis for Influenza virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) ES (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004376-64 Sponsor Protocol Number: EURO17-09 Start Date*: 2018-01-10
    Sponsor Name:Eurocine Vaccines AB
    Full Title: A Phase I/II, randomised, multicentre, placebo-controlled, partially-blinded, parallel-group study to assess the safety, tolerability and immune response following vaccination with ImmunoseTM FLU i...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000728-27 Sponsor Protocol Number: V118_18 Start Date*: 2015-09-30
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to ...
    Medical condition: Profylaxis for Influenza virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: EE (Completed) PL (Completed) LV (Completed) CZ (Completed) LT (Completed) RO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-001094-25 Sponsor Protocol Number: 200188 Start Date*: 2013-07-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, open-label, non-randomised, multi-centre, single dose study to assess the immunogenicity and safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Influs...
    Medical condition: Immunization of healthy adults against influenza
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10059430 Influenza immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004763-40 Sponsor Protocol Number: GQM14 Start Date*: 2017-04-05
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) in Pregnant Women
    Medical condition: Prophylaxix of influenza in Pregnant Women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-021073-36 Sponsor Protocol Number: 113314 Start Date*: 2010-09-17
    Sponsor Name:GlaxoSmithKline
    Full Title: Estudio fase III, doble ciego aleatorizado para evaluar la inmunogenicidad y seguridad de la vacuna antigripal tetravalente de GSK Biologicals GSK2282512A (FLU Q-QIV) comparada con la vacuna antigr...
    Medical condition: Gripe Estacional
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022000 Influenza LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-003760-27 Sponsor Protocol Number: INCENTIVE-QIV-3-EU Start Date*: 2021-09-21
    Sponsor Name:Université Libre de Bruxelles
    Full Title: INCENTIVE-QIV-3-EU: Immunogenicity, molecular profiling of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra®) administered by the intramuscular route in participants aged 6 to 8 months
    Medical condition: Prophylaxis of Influenza (Northern Hemispher 2021-2022 and 2022-2023 season) in Children aged 6-8 months
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005682-13 Sponsor Protocol Number: 76061 Start Date*: 2021-04-22
    Sponsor Name:Radboudumc
    Full Title: Exploratory study into age-related immunological differences related to immunogenicity in influenza vaccination and herpes zoster vaccination
    Medical condition: Influenza Herpes Zoster
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013326-17 Sponsor Protocol Number: MI-CP208 Start Date*: 2013-05-20
    Sponsor Name:MedImmune, LLC
    Full Title: A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children
    Medical condition: Prophylaxis of influenza
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001557-41 Sponsor Protocol Number: Adim-QIS-01 Start Date*: 2016-09-09
    Sponsor Name:Adimmune Corporation
    Full Title: A Phase III, Multi-center, Single-dose, Randomized, Double-blind, Non-inferiority and Lot-to-lot Consistency Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Infl...
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:37:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA